Rapid and Accurate: Point-of-Care Molecular Diagnostics Market Set to Reach USD 2.8 Billion in 2022, Growing at a CAGR of 8.2% from 2023 to 2033

As per the study initiated by Evolve Business Intelligence, the global Point of Care Molecular Diagnostics Market size accounted for USD 2.8 Billion in 2022, growing at a CAGR of 8.2% from 2023 to 2033. Point-of-care molecular diagnostics refers to the use of portable, easy-to-use devices that allow for rapid and accurate diagnostic testing in a clinical or non-clinical setting, without the need for laboratory equipment or specialized personnel. These devices use molecular techniques, such as polymerase chain reaction (PCR) or nucleic acid amplification, to detect specific genetic material, such as DNA or RNA, in a patient's sample, such as blood, saliva, or urine. Point-of-care molecular diagnostics has many potential applications, such as diagnosing infectious diseases, detecting genetic disorders, and monitoring cancer treatment. It offers several advantages over traditional laboratory-based testing, such as faster turnaround times, improved patient outcomes, and reduced healthcare costs. The global market for point-of-care molecular diagnostics is growing rapidly, driven by advances in technology, increased demand for rapid and accurate diagnostics, and the growing need for decentralized healthcare systems.
Request a Free Sample Report or PDF Copy: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=019128
Key Highlights:
• The global Point of Care Molecular Diagnostics Market size was valued at USD 2.8 billion in 2022 growing at a CAGR of 8.2% from 2023 to 2033.
• North America dominated the market in 2022
• Asia Pacific is expected to fastest-growing at the highest CAGR from 2023 to 2033
Evolve Business Intelligence has published a new market research report on the Global Point of Care Molecular Diagnostics Market focusing on various aspects including market size and forecast, market dynamics, competitors' market share analysis, market size in terms of value and volume, SWOT analysis, product benchmarking, key players recent developments, and opportunities, among others. The market has also been analyzed based on 4 indicators in the market dynamic chapter which include Drivers, Restraints, Key Trends, and Challenges. The overall sum of these sections will help to understand the best strategies to be adopted to prosper in this industry over short and long terms. The quantitative analysis includes our authentic findings out of this research study where we provided additional insight into what our readers can do to embrace new opportunities or plan against threats that might hinder the market.
In terms of COVID 19 impact, the Point of Care Molecular Diagnostics Market report also includes the following data points:
• COVID19 Impact on Point of Care Molecular Diagnostics Market size
• End-User/Industry/Application Trend, and Preferences
• Government Policies/Regulatory Framework
• Key Players Strategy to Tackle Negative Impact/Post-COVID Strategies
• Opportunity in Point of Care Molecular Diagnostics Market
Buy the Latest Copy of the Report Now at a Higher Discount: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=019128
Key Players
Some of the major Point of Care Molecular Diagnostics Market players holding high market share include Abbott, Bayer AG, F. Hoffmann-La Roche AG, and Nova Biomedical. These players use partnership and collaboration as key strategy to gain significant market share to compete with market leaders.
The key players profiled in the report are:
• Abbott
• Bayer AG
• F. Hoffmann-La Roche
• Nova Biomedical
• QIAGEN
• Nipro Diagnostics
• Danaher
• Bio-Rad Laboratories, Inc
• bioMérieux
• Agilent Technologies, Inc
• Abaxis
Segmental Analysis
Market Segment By Application with the focus on market share, consumption trend, and growth rate of Point of Care Molecular Diagnostics Market:
o Oncology
o Hematology
o Prenatal Testing
o Endocrinology
Market Segment By Technology with a focus on market share, consumption trend, and growth rate of Point of Care Molecular Diagnostics Market:
o PCR-based
o Genetic Sequencing-based
o Hybridization-based
o Microarray-based
Market Segment By End Use with focus on market share, consumption trend, and growth rate of Point of Care Molecular Diagnostics Market:
o Decentralized Labs
o Hospitals
o Home-care
o Assisted Living Healthcare Facilities
Parameters Details
Market Size (2022) USD 2.8 Billion
CAGR (2023 to 2033) 8.2%
Market Segmentation Application, Technology, and End Use
Country Covered US, Canada, Mexico, UK, Germany, France, Italy, Spain, Nordic Countries, BeNeLux, Rest of Europe, China, India, Japan, South Korea, Indonesia, Malaysia, Australia, Rest of Asia Pacific, Middle East & Africa, and South America
For more information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=019128
Global Point of Care Molecular Diagnostics Market Geographic Coverage:
• North America
o US
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Nordic Countries
o Benelux
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Indonesia
o Malaysia
o Australia
o Rest of Asia Pacific
• Middle East and Africa
o Saudi Arabia
o UAE
o Egypt
o South Africa
o Rest of MEA
• Latin America
o Mexico
o Brazil
o Argentina
o Rest of Latin America
Reasons to Buy this Report:
• Detail analysis of the impact of market drivers, restraints, and opportunities
• Competitive Intelligence provides an understanding of the ecosystem
• Details analysis of the Total Addressable Market (TAM) of your products
• Investment Pockets and New Business Opportunities
• Demand-supply gap analysis
• Strategy Planning

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.

This release was published on openPR.